Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC108 + Furmonertinib +/- Toripalimab in EGFR-mutated NSCLC
NCT05821933Phase 2Recruiting
- Sponsor
- RemeGen
- Start
- Sep 2023
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RC108 in non-small cell lung cancer (NSCLC), sponsored by RemeGen. Started Sep 2023; status: recruiting.
02
Drugs
RC108
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05821933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05821933.